close

Fenwick & West Represents AC Immune in Licensing Agreement with Piramal

May 16, 2014

Fenwick & West LLP represented AC Immune SA, a Swiss-based biopharmaceutical company and a leader in Alzheimer’s disease drug development, in a licensing agreement with Piramal Imagining SA, a fully owned subsidiary of Piramal Enterprises, Ltd, which was formed in 2012 with the acquisition of the molecular imagining research and development portfolio of Bayer Pharma AG. This exclusive, worldwide license agreement will allow Piramal global rights for the research, development and commercialization of AC Immune’s Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer’s disease (AD) and potential Tau-related disorders. Under the terms of the agreement, AC Immune and Piramal will work in collaboration to efficiently advance several lead candidates through late pre-clinical radio-pharmacology development. AC Immune will receive an undisclosed upfront payment and is eligible for significant milestone payments on products achieving development goals in AD and other Tauopathies, including tiered royalties on the net sales of products resulting from the partnership.

The Fenwick transaction team was led by licensing partner Jake Handy and licensing associate Claire O’Callaghan.